Boehringer Ingelheim Launches Metalyse 25 mg in Egypt Following Approval by the Egyptian Drug Authority

Strategic Insights -

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, has introduced Metalyse 25 mg (Tenecteplase) in Egypt as a treatment for acute ischemic stroke (AIS), marking a crucial step forward in the country's fight against this life-threatening condition. The launch follows the recent approval by the Egyptian Drug Authority, and the company will officially introduce the treatment during a medical conference on October 17, inviting 150 healthcare professionals. The introduction of this treatment is a significant development, but public awareness about the early signs and the need for urgent medical attention is equally important.

Key Takeaways:

  • Metalyse 25 mg (Tenecteplase) has been introduced in Egypt as a treatment for acute ischemic stroke (AIS), following its approval by the Egyptian Drug Authority.
  • The treatment will be officially introduced during a medical conference on October 17, with the invitation of 150 healthcare professionals.
  • Effective treatments like Metalyse 25 mg are now available to improve recovery and outcomes for patients suffering from acute ischemic stroke.
  • The partnership between Boehringer Ingelheim and The Egyptian Society of Neurology, Psychiatry and Neurosurgery, Stroke Chapter, will help update the national protocol for acute ischemic stroke treatment in Egypt, aligning it with the latest evidence-based medical practices.
  • Dr. Hussam Salah, Dean of Faculty of Medicine at Cairo University and Professor of Neurology, emphasized the importance of public awareness about the early signs and the need for urgent medical attention.
  • Dr. Ahmed El-Bassiouni, Director of Intervention Neurology Unit at Ain Shams University, highlighted the importance of early intervention in treatment outcomes, stating that every minute after stroke onset results in the loss of millions of brain cells.
  • Clocking the ideal time window for achieving the best treatment outcome is within 4.5 hours of symptom onset.
  • Common warning signs of stroke include numbness on one side of the body, difficulty concentrating, speech impairment, or vision problems in one or both eyes.
  • In Egypt, the overall prevalence of stroke is approximately 963 cases per 100,000 people, with an estimated 150,000 to 210,000 new cases annually.
  • Stroke ranks as the third leading cause of death in the country, accounting for 6.4% of all deaths.
  • While only 12.7% of Egyptians are over 50, around 20.5% of stroke cases occur among younger adults.
  • Dr. Ahmed El-Bassiouni also mentioned that stroke risk is heightened by factors such as smoking, hypertension, high cholesterol, and diabetes, often linked to obesity and unhealthy lifestyle habits.

Statistics:

  • 963 cases per 100,000 people: the overall prevalence of stroke in Egypt.
  • 150,000 to 210,000 new cases annually: the estimated number of new stroke cases in Egypt.
  • 6.4% of all deaths: the percentage of deaths in Egypt attributed to stroke.
  • 20.5% of stroke cases occur among younger adults: highlighting the alarming rise of stroke cases among younger populations.
  • 12.7% of Egyptians are over 50: indicating that a significant portion of the population is at risk of stroke due to age.

Sources:

  • Dailynewsegypt
  • Boehringer Ingelheim
  • Egyptian Drug Authority
  • Egyptian Society of Neurology, Psychiatry and Neurosurgery, Stroke Chapter
  • Dr. Hussam Salah
  • Dr. Ahmed El-Bassiouni
  • Ain Shams University
  • Prof. Mohamed Mes